Lexaria Bioscience Corp.

The momentum for this stock is not very good. Lexaria Bioscience Corp. is a mediocre stock to choose.

News

Lexaria Bioscience (NASDAQ:LEXX) Trading Down 4.1%

Zolmax Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX - Get Free Report) fell 4.1% during mid-day trading on Thursday . The stock traded as low as $3.27 and last traded at $3.30. 72,044 shares traded hands...\n more…

Lexaria Releases Strategic Letter from the Outgoing CEO

Accesswire KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms is pleased to provide...\n more…

Lexaria Welcomes Industry Veteran as New CEO

Accesswire Outgoing CEO, Chris Bunka, to remain on as Chairman of the Board of Directors and Executive Strategic Advisor KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp...\n more…

Lexaria Bioscience says second GLP-1 human pilot study shows zero adverse events

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

Accesswire Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under 'fed' conditionsDehydraTECH-treated Rybelsus® does absorb through a...\n more…

Lexaria's Study Suggests Improved Drug Absorption With Food

TipRanks Financial Blog Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has announced preliminary findings from its second human pilot study, indicating that its Dehyd...\n more…